Patents by Inventor Robert L. Coffman

Robert L. Coffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USER INTERFACES FOR PRESENTING INDICATIONS OF INCOMING CALLS
    Publication number: 20240163358
    Abstract: In some embodiments, an electronic device displays an incoming call user interface in response to receiving an indication of an incoming call. In some embodiments, the incoming call user interface is displayed overlaid on a respective user interface that is optionally associated with an application other than the application associated with the incoming call.
    Type: Application
    Filed: October 23, 2023
    Publication date: May 16, 2024
    Inventors: Jae Woo CHANG, Nathan DE VRIES, Marcel VAN OS, Christopher Patrick FOSS, Heena KO, Patrick L. COFFMAN, Robert GARCIA, III
  • Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer
    Patent number: 11918648
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: March 5, 2024
    Assignees: MERCK SHARP & DOHME LLC, TRISALUS LIFE SCIENCES, INC.
    Inventors: Ying Yu, Andrew Evan Denker, Svetlana Sadekova, Uyen Truong Phan, Robert A. Kastelein, David Ross Kaufman, Robert L. Coffman, Cristiana Guiducci, Robert S. Janssen
  • Toll-like receptor antagonist compounds and methods of use
    Patent number: 11827641
    Abstract: The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: November 28, 2023
    Assignee: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Albert Frederick Candia, III, Richard Thomas Beresis, Robert L. Coffman
  • ACTIVE BOOSTER IMMUNIZATION AGAINST TETANUS, DIPHTHERIA AND PERTUSSIS
    Publication number: 20230072809
    Abstract: The present disclosure relates to immunogenic compositions comprising tetanus, diphtheria, and acellular pertussis (Tdap) antigens, and a toll-like receptor 9 (TLR9) agonist, such as oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions may further comprise an aluminum salt adjuvant to which the Tdap antigens are adsorbed. The immunogenic compositions are suitable for active booster immunization against tetanus, diphtheria, and pertussis in an individual in need thereof.
    Type: Application
    Filed: March 9, 2021
    Publication date: March 9, 2023
    Applicants: Dynavax Technologies Corporation, Serum Institute of India Private Limited
    Inventors: John D. CAMPBELL, Robert L. COFFMAN, Randall N. HYER, Robert S. JANSSEN, David NOVACK, Martin GOHLKE, Maureen URBAN, Sunil GAIROLA, Umesh SHALLIGRAM, Manish GAUTUM, Harish RAO
  • TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE
    Publication number: 20220298162
    Abstract: The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.
    Type: Application
    Filed: May 20, 2022
    Publication date: September 22, 2022
    Applicant: Dynavax Technologies Corporation
    Inventors: Albert Frederick CANDIA, Richard Thomas BERESIS, Robert L. COFFMAN
  • Toll-like receptor antagonist compounds and methods of use
    Patent number: 11370794
    Abstract: The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I), and pharmaceutical compositions thereof, are antagonists of toll-like receptors such as TLR7, TLR8, and/or TLR9. In certain embodiments, compounds of the invention are useful for inhibiting immune response and treating diseases associated with undesirable immune response.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: June 28, 2022
    Assignee: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Albert Frederick Candia, III, Richard Thomas Beresis, Robert L. Coffman
  • COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
    Publication number: 20210196819
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (T1119) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: August 21, 2020
    Publication date: July 1, 2021
    Inventors: Ying YU, Andrew Evan DENKER, Svetlana SADEKOVA, Uyen Truong PHAN, Robert A. KASTELEIN, David Ross KAUFMAN, Robert L. COFFMAN, Cristiana GUIDUCCI, Robert S. JANSSEN
  • Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
    Patent number: 10751412
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 25, 2020
    Assignees: MERCK SHARP & DOHME CORP., DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Ying Yu, Andrew Evan Denker, Svetlana Sadekova, Uyen Truong Phan, Robert A. Kastelein, David Ross Kaufman, Robert L. Coffman, Cristiana Guiducci, Robert S. Janssen
  • Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
    Patent number: 10722591
    Abstract: The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker. The present disclosure also related to methods for preparation of the cleavable conjugates, uses thereof for stimulating an effective immune response, and uses thereof for the treatment of cancer.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: July 28, 2020
    Assignee: Dynavax Technologies Corporation
    Inventors: Robert L. Coffman, Stewart D. Chipman, Radwan Kiwan, Samuel Zalipsky, Gary S. Ott
  • Branched chimeric compounds, and methods of use thereof
    Patent number: 10548975
    Abstract: The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: February 4, 2020
    Assignee: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Gary S. Ott, Robert J. Milley, Robert L. Coffman, Radwan Kiwan, Holger Kanzler
  • TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE
    Publication number: 20190345161
    Abstract: The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.
    Type: Application
    Filed: November 9, 2017
    Publication date: November 14, 2019
    Applicant: Dynavax Technologies Corporation
    Inventors: Albert Frederick CANDIA, III, Richard Thomas BERESIS, Robert L. COFFMAN
  • BRANCHED CHIMERIC COMPOUNDS, AND METHODS OF USE THEREOF
    Publication number: 20190240323
    Abstract: The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.
    Type: Application
    Filed: April 20, 2018
    Publication date: August 8, 2019
    Inventors: Gary S. OTT, Robert J. MILLEY, Robert L. COFFMAN, Radwan KIWAN, Holger KANZLER
  • Administration of polynucleotide toll-like receptor 9 agonists for treating cancer
    Patent number: 10369168
    Abstract: The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: August 6, 2019
    Assignee: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Cristiana Guiducci, Robert L. Coffman
  • Linear chimeric compounds and methods of use thereof
    Patent number: 10350290
    Abstract: The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: July 16, 2019
    Assignee: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Gary S. Ott, Robert J. Milley, Robert L. Coffman, Radwan Kiwan, Holger Kanzler
  • ADMINISTRATION OF POLYNUCLEOTIDE TOLL-LIKE RECEPTOR 9 AGONISTS FOR TREATING CANCER
    Publication number: 20190151345
    Abstract: The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
    Type: Application
    Filed: September 25, 2018
    Publication date: May 23, 2019
    Inventors: Cristiana GUIDUCCI, Robert L. COFFMAN
  • CLEAVABLE CONJUGATES OF TLR7/8 AGONIST COMPOUNDS, METHODS FOR PREPARATION, AND USES THEREOF
    Publication number: 20190151462
    Abstract: The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker. The present disclosure also related to methods for preparation of the cleavable conjugates, uses thereof for stimulating an effective immune response, and uses thereof for the treatment of cancer.
    Type: Application
    Filed: November 13, 2018
    Publication date: May 23, 2019
    Applicant: Dynavax Technologies Corporation
    Inventors: Robert L. COFFMAN, Stewart D. CHIPMAN, Radwan KIWAN, Samuel ZALIPSKY, Gary S. OTT
  • BRANCHED AND LINEAR CHIMERIC COMPOUNDS, POLYNUCLEOTIDES, USES AND METHODS FOR PREPARATION THEREOF
    Publication number: 20180360954
    Abstract: The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.
    Type: Application
    Filed: April 20, 2018
    Publication date: December 20, 2018
    Inventors: Gary S. OTT, Robert J. MILLEY, Robert L. COFFMAN, Radwan KIWAN, Holger KANZLER
  • Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung
    Patent number: 10111899
    Abstract: The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: October 30, 2018
    Assignee: Dynavax Technologies Corporation
    Inventors: Cristiana Guiducci, Robert L. Coffman
  • INTRAPULMONARY ADMINISTRATION OF POLYNUCLEOTIDE TOLL-LIKE RECEPTOR 9 AGONISTS FOR TREATING CANCER OF THE LUNG
    Publication number: 20180264023
    Abstract: The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Inventors: Cristiana GUIDUCCI, Robert L. COFFMAN
  • COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
    Publication number: 20180169229
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: May 26, 2016
    Publication date: June 21, 2018
    Applicants: MERCK SHARP & DOHME CORP., DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Ying YU, Andrew Evan DENKER, Svetlana SADEKOVA, Uyen Truong PHAN, Robert A. KASTELEIN, David Ross KAUFMAN, Robert L. COFFMAN, Cristiana GUIDUCCI, Robert S. JANSSEN